Alkermes’ Earnings Call Highlights Growth and LUMRYZ Surge

Alkermes plc ((ALKS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Alkermes’ latest earnings call struck a notably upbeat tone, with management emphasizing strong revenue growth, a fast start for newly acquired sleep drug LUMRYZ, and a sizable adjusted EBITDA beat. While they acknowledged a GAAP loss, higher leverage, and near‑term margin pressure from integration and pipeline investment, executives framed these as manageable trade‑offs for a larger, faster‑growing portfolio.

Proprietary Portfolio Fuels Double-Digit Topline Growth

Net sales from Alkermes’ proprietary products climbed 38% year over year to $338.1 million in the first quarter, driving total revenue to $392.9 million. The company highlighted this as evidence that its core psychiatry and addiction franchises are scaling, even before fully capturing the contribution from the Avadel acquisition.

Key Brands Deliver Solid, Diversified Performance

Flagship injectable VIVITROL generated $112.4 million in Q1 sales, with full‑year guidance set at $460 million to $480 million. ARISTADA brought in $93.8 million and is expected to reach $365 million to $385 million in 2026, while LYBALVI posted $92.4 million, up 32% year over year, supporting a full‑year outlook of $380 million to $400 million.

LUMRYZ Acquisition and Launch Momentum Impress

Alkermes closed its takeover of Avadel in mid‑February and reported about $39.5 million of LUMRYZ net sales in the six weeks post‑close, with roughly $72 million booked for the full quarter. The company exited Q1 with around 3,600 patients on therapy, a 28% year‑over‑year increase in brand patient count, and guided LUMRYZ net sales to $350 million to $370 million for 2026.

Adjusted EBITDA Surprises to the Upside

Adjusted EBITDA reached $80.3 million in Q1, far surpassing prior guidance of $30 million to $50 million and prompting an improved outlook. Management now expects second‑quarter adjusted EBITDA between $100 million and $120 million and forecasts full‑year adjusted EBITDA in a positive range of $105 million to $135 million on a GAAP basis.

Purchase Price Accounting Tweaks Ease Cost Burden

After refining purchase price accounting for the Avadel deal, Alkermes lowered its expected LUMRYZ inventory step‑up expense for 2026 to about $105 million from roughly $150 million previously. As a result, projected 2026 cost of goods sold was cut to $320 million to $340 million, and expected amortization of intangibles was reduced to $75 million to $85 million.

Orexin Pipeline Advances on Multiple Fronts

The company underscored progress across its orexin‑focused pipeline, with the Brilliance Phase III program for alixorexton now enrolling patients with narcolepsy types 1 and 2. Additional trials, including Vibrance‑2 in NT2 and Vibrance‑3 in idiopathic hypersomnia, are moving ahead, alongside new molecules ALKS 7290 for ADHD and ALKS 4510 for fatigue in multiple sclerosis and Parkinson’s disease.

Leverage Rises as Balance Sheet Funds Expansion

To finance Avadel, Alkermes deployed about $775 million of cash and tapped $1.525 billion of term loans maturing in 2031, ending the quarter with approximately $538 million in cash and investments. Management acknowledged the higher leverage but pointed to strong cash flow potential and noted it repurchased around 1 million shares for $28 million, with $172 million still authorized.

GAAP Loss Highlights Cost of Growth and Integration

Despite the adjusted profitability, Alkermes reported a GAAP net loss of $66.5 million and negative GAAP EBITDA of $30.1 million in Q1. The shortfall reflects acquisition‑related charges, inventory step‑up, and stepped‑up operating costs as the company integrates LUMRYZ and ramps late‑stage development programs.

R&D Spending Climbs with Pipeline Acceleration

Research and development expenses rose to $103.3 million from $71.8 million a year earlier, an increase of about $31.5 million. The company attributed the step‑up mainly to the Phase III launch of alixorexton and broader orexin program activity and signaled that R&D will rise further in the second quarter to between $110 million and $120 million.

SG&A Inflation Reflects Acquisition and Higher Base

Selling, general, and administrative expenses reached $264.6 million in the quarter, including approximately $55 million of one‑time costs tied to closing the Avadel deal. Excluding these, adjusted SG&A of $209.4 million still marked a clear increase from $171.7 million a year ago, underscoring a higher ongoing run‑rate after integrating LUMRYZ.

Inventory Step-Up Creates Short-Term Margin Drag

Cost of goods sold totaled $61.6 million in Q1, inflated by the LUMRYZ inventory step‑up; management noted that COGS would have been $48.9 million without it. For the second quarter, COGS is forecast at $85 million to $95 million as the company absorbs a full quarter of LUMRYZ and continues amortizing the stepped‑up inventory values.

Financing Mix Reduces Liquidity Headroom

The combination of a large cash outlay and new term loans has reduced Alkermes’ cash cushion and increased its debt load in the near term. Executives emphasized plans to use operating cash flow to pay down borrowings over time, but investors are left weighing the higher financial leverage against the growth potential of the expanded portfolio.

Gross-to-Net Dynamics Weigh on Pricing Power

For LYBALVI, gross‑to‑net discounts and allowances were around 33% in the first quarter and are expected to widen into the mid‑30% range over the year, compressing effective pricing. Management also cautioned that an approximately $14 million gross‑to‑net benefit in Q1 largely reflected timing and patient mix and should not be considered a recurring uplift.

Competitive Landscape Adds Strategic Uncertainty

Alkermes acknowledged rising competitive risks, notably Eli Lilly’s entry into the orexin field, which both validates the mechanism and raises future pressure. The company is also watching for potential multisource generic entrants to Xyrem around 2027, which could reshape the oxybate market even though no visible impact on LUMRYZ has emerged yet.

Tax Outlook Softens Versus Prior Expectations

Management revised its 2026 income tax view, now expecting neither a material tax expense nor benefit for the year. This is a modest negative shift from a previously anticipated roughly $20 million benefit and slightly tempers the net income outlook despite the strong operational trajectory.

Guidance Signals Strong Growth with Managed Headwinds

For 2026, Alkermes now expects revenue to exceed $1.7 billion and adjusted EBITDA to surpass $370 million, even as it projects a GAAP net loss of $70 million to $90 million and GAAP EBITDA of $105 million to $135 million. Second‑quarter guidance calls for proprietary net sales of $385 million to $405 million, R&D of $110 million to $120 million, SG&A of $210 million to $220 million, and adjusted EBITDA of $100 million to $120 million.

Alkermes’ earnings call painted a picture of a company trading near‑term margin and balance sheet comfort for accelerated growth and a deeper pipeline. With LUMRYZ off to a strong start, core brands holding up, and orexin programs advancing, management is leaning into investment despite GAAP losses and higher leverage, a stance investors will watch closely as 2026 unfolds.